Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > zenith halted?

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Aug 04, 2021 9:20pm

179 Views

Post# 33652864

RE:RE:RE:RE:zenith halted?

yes when i type in zeni.p on stockhouse it brings up the astrazeneca trial with zen 3694 .the shares don't trade much but are quite low .14 canadian when they do, so what gives with the zhclf on the otc US board trading at levels much higher? Need clarification

ZENI.P is the ticker for Zenith Capital Corporation, a "capital pool" company based in Vancouver, BC. Many brokerages and stock web sites make this error.

See Zenith Epigenetics FAQs #3

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports